Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up
Connect Twitter with Market Wire News

Teladoc Stock Is Returning to Long-Term Pivotal Zones


home / news releases / Teladoc Stock Is Returning to Long-Term Pivotal Zones

  • January, 14 2022 01:10 PM
  • |
  • InvestorPlace
  • |
    • MRNA
    • MRNA Quote
    • MRNA Short
    • MRNA News
    • MRNA Articles
    • MRNA Message Board

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

Wall Street investors are very fickle these days. They are showing no commitment in either direction for longer than a few hours at a time. This makes it very difficult to commit capital with great conviction. This dynamic is part of what has impacted Teladoc (NYSE:TDOC) stock. TDOC has given up the entire relief rally out of the pandemic. It is now a falling machete seemingly going into an abyss.

Source: Postmodern Studio / Shutterstock.com

My argument today will be a tough sell for most readers, but stick with me a bit longer. It’s hard to convince people that a stock has value when it’s unable to attract bids. Therefore, I will use data to support my claims.

Teladoc stock currently presents a compelling investment for the long term. But first it is important to note that nothing is absolute, so I consider this a starter position.

With so much uncertainty on Wall Street today, investors should leave room for error.

TDOC Stock Has Solid Fundamental Footing

Fundamentally, the business is healthy and that’s not just an opinion. The proof is in the company’s profit and loss official statement. Management delivered an average of 70% growth in revenues and gross profits since 2014. This should earn them the benefit of the doubt on the competence front.

  • 7 Stocks to Buy That Doubled in 2021 and Could Again in 2022

Critics can point to the fact that they still lose a lot of money, and I don’t disagree. But clearly this is a growth stock, so it’s okay to overspend for now. Amazon (NASDAQ:AMZN) did it for over a decade before the naysayers finally understood.

Moreover, a great financial metric to measure value of a growth company is its price-to-sales (P/S). TDOC stock’s P/S is 7x, which is lower than Apple (NASDAQ:AAPL), Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL) and Facebook (NASDAQ:FB). This is despite the fact that it eclipses their growth rates by miles. As long as management continues to maintain the pace, valuation will normalize over time.

Often the problem of a falling stock is not in the fundamentals. Frequently it is investor expectations that are out of whack. Such was the case in TDOC, because the 2020 results were enormous. They grew subscriptions by nearly 40%, which makes it a tough comp to roll over. Indeed, 2021 was a complete dud with barely any growth. But still they have over 50 million subs, which is a good base for this year.

Demand Will Not Be a Problem

Source: Charts by TradingView

The tele-health concept makes a lot of sense on so many levels. Much like many habits we’ve developed during the crisis, this one is not a fad. The need for more efficient medical solutions is likely to rise with the global digitization trend.

The more compelling side of the argument for TDOC stock today is in its chart. Oddly enough, it broke out in January 2020 a full month before the pandemic crisis. I would have expected conspiracy theorists to be all over that one. The stock never fell like the rest of the market into a March low that year.

In fact, when the indices finally bottomed in March, TDOC stock was already up 50% from January. Currently, it is much lower than both levels.

Moreover, Teladoc stock is now at a level that has history. The bears crashed it back in October 2018. Then the bulls rocked it in January 2020. This makes the zone a sharp point of contention and on two occasions, 14 months apart. When stocks fall back into such battle zones, they often find buyers lurking.

It won’t necessarily be a hard line in the sand, but it’s the opposite of chasing stocks into runaway rallies. Buying Teladoc at these levels is not likely to be a flagrant mistake. Nevertheless, investors would do well to take only partial positions to start. The indices are still hovering near highs, so we should leave room for surprise corrections.

On the date of publication, Nicolas Chahine did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.

Nicolas Chahine is the managing director of SellSpreads.com.

More From InvestorPlace

  • Stock Prodigy Who Found NIO at $2… Says Buy THIS Now
  • Man Who Called Black Monday: “Prepare Now.”
  • #1 EV Stock Still Flying Under the Radar
  • Crypto-read-this-first/?cid=MKT555962&eid=MKT589180&utm_source=quotemedia&utm_medium=referral">Interested in Crypto? Read This First...

The post Teladoc Stock Is Returning to Long-Term Pivotal Zones appeared first on InvestorPlace.

Get Email and Text Alerts for (NASDAQ:MRNA)

Get Email and Text Alerts for (NASDAQ:MRNA)

News, Short Squeeze, Breakout and More Instantly...

Tags
  • Healthcare
Share This Post

Market Wire News is a media platform, the information on this page was provided by InvestorPlace via Quote Media. Read our full disclaimer.

Link your Twitter Account to Market Wire News

When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.

Be alerted of any news about your stocks and see what other stocks are trending.


Contact the Author

Stock Information

Moderna Inc. Company Name:

MRNA Stock Symbol:

NASDAQ Market:

Moderna Inc. Website:

Teladoc Stock Is Returning to Long-Term Pivotal Zones

MENU
MRNA MRNA Quote MRNA Short MRNA News MRNA Articles MRNA Message Board
Get MRNA Alerts

News, Short Squeeze, Breakout and More Instantly...

Connect Twitter with Market Wire News
RECENT MRNA NEWS
  • MRNA - Why Pfizer Stock Is Rising Today While Moderna and Novavax Are Sliding

    Shares of Pfizer (NYSE: PFE) were up 2.5% as of 11:35 a.m. ET on Friday after jumping as much as 4% earlier in the day. Meanwhile, the stocks of two other COVID-19 vaccine makers were declining. Moderna 's (NASDAQ: MRNA) shares were down 4.7%. Novavax (NASDAQ: NVAX) ...

  • MRNA - Here's How Moderna Could Top $450 Again

    Moderna (NASDAQ: MRNA) shares have dropped 70% since their record high of more than $450 last August. There are a couple of reasons. The first has to do with the general investment environment: Investors aren't flocking to vaccine stocks as they did earlier in the pandemic. The seco...

  • MRNA - 3 Blue-Chip Tech Stocks to Buy Now

    InvestorPlace - Stock Market News, Stock Advice & Trading Tips Buy these blue-chip tech stocks after earnings beats and bullish price patterns that can’t be beat. Advanced Micro Devices ( AMD ) is poised to break out of a bear market downtrend following earnings trifect...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Message Boards
  • Trending Stocks
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Join us on Discord

Join us on Discord

Follow us on discord to get immediate notifications!

Check out the New Market Wire News Discord Bot

Discord


Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email [email protected].

WATCH LIVE TRENDING STOCKS

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected
Follow @MarketWN

Contact

Privacy

Terms of Service

Disclaimer

© 2020 Market Wire News